Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-22BP/LNP Compound in Refractory Malignant Solid Tumors
NCT07100210Phase 1Recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL-22BP/LNP compound in solid tumor. Primary endpoint: Incidence of Dose-Limiting Toxicities and Treatment Interruptions Due to Adverse Events at 2 months. Started Jan 2025; status: recruiting.
02
Drugs
IL-22BP/LNP compound
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07100210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100210.